A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2007 |
| End Date: | April 2012 |
A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will
assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with
advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in
cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and
tolerability of SB939 in combination with standard azacitidine therapy.
We found this trial at
2
sites
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials